Both face patent cliffs and regulatory headwinds, but their balance sheets and cash generation tell starkly different stories.
Bristol-Myers Squibb Co. (BMY) News
Latest headlines that mention BMY, newest first · each headline opens the original publisher
- Last price
- $59.58
- Day change
- -0.20%
- Next earnings
- 2026-10-29 BMO
BMY headlines
last 30 daysIf you are looking for yield and can think long-term, you'll want to consider Bristol Myers Squibb and Realty Income today.
Bristol Myers Squibb isn't a growth stock, but it may offer something to bargain hunters and dividend seekers.
AbbVie boasts stronger revenue growth and free cash flow, while Bristol Myers Squibb trades at half the valuation with nearly double the profit margin.
Johnson & Johnson's revenue base runs roughly double Bristol-Myers Squibb's, with the gap showing signs of widening over the past two years.
Investors seeking a high yield and stable fundamentals in the healthcare sector need look no further than Bristol Myers Squibb. The post This Pharma Giant Has The Right Medicine For Income Investors appeared first on Investor's Business Daily .
Bristol Myers Squibb trades at a fraction of Eli Lilly's valuation while generating substantial free cash flow, but concentration risk and explosive growth tell very different stories.
Pfizer and Bristol Myers Squibb pair big dividends with growing drug pipelines, a rare combination for income-focused pharma investors.
With this pharma company trading for less than 10 times earnings, the market remains very uncertain about its stock and looming patent cliff.
Bristol Myers Squibb raised its 2026 sales outlook in July, while Novo Nordisk expects its sales to be flat at best this year, yet Bristol Myers Squibb trades at the lower earnings multiple.
Both face patent cliffs and pay generous dividends, but only one of them can tell you where its next wave of growth is coming from.
Bristol Myers Squibb trades at a steep valuation discount, while Johnson & Johnson's stronger margins and lower debt offer stability. But patent cliffs and litigation risks complicate both cases.
The company's strong pipeline and newer approved drugs should be enough to allay patent expiration concerns.
AbbVie's immunology franchise is firing on all cylinders while Bristol Myers Squibb navigates revenue declines and legal uncertainty.
As management tackles key issues head-on, Bristol Myers Squibb stock offers a steady 4% yield, with further upside potential.
Also mentioned with BMY
30dHeadlines that tag both tickers
BMY news alerts
Get an alert by email or push when a new headline mentions BMY.
More news
News headlines aggregated from third-party publishers via public RSS feeds and tagged with the tickers they mention. Frenzy Capital does not publish or endorse the content; clicking a headline opens the original publisher in a new tab.